The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis.

Q4 Medicine

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI:10.31138/mjr.171223.tej

Sotirios G Tsiogkas, Carlo Perricone, Dimitrios P Bogdanos

{"title":"The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis.","authors":"Sotirios G Tsiogkas, Carlo Perricone, Dimitrios P Bogdanos","doi":"10.31138/mjr.171223.tej","DOIUrl":null,"url":null,"abstract":"Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on patient-reported outcomes (PROs) when used for the management of PsA.Methods: We utilised a narrative review approach as we searched the available literature for articles to be included in our study.Results: JAKi have been found to be effective in inducing better PRO responses compared to placebo. These findings have been consistent across various patient populations, including those with active PsA, those with an inadequate response to conventional therapies, and those with comorbidities. The evidence supporting the benefits of JAKi on PROs in PsA is compelling, demonstrating consistent improvements in pain, physical function, fatigue, and quality of life.Conclusion: Numerous studies have demonstrated the the efficacy of JAKi in improving PROs in patients with PsA.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"20-26"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094440/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.171223.tej","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on patient-reported outcomes (PROs) when used for the management of PsA.

Methods: We utilised a narrative review approach as we searched the available literature for articles to be included in our study.

Results: JAKi have been found to be effective in inducing better PRO responses compared to placebo. These findings have been consistent across various patient populations, including those with active PsA, those with an inadequate response to conventional therapies, and those with comorbidities. The evidence supporting the benefits of JAKi on PROs in PsA is compelling, demonstrating consistent improvements in pain, physical function, fatigue, and quality of life.

Conclusion: Numerous studies have demonstrated the the efficacy of JAKi in improving PROs in patients with PsA.

查看原文本刊更多论文

JAK抑制剂对银屑病关节炎患者报告结果的影响

目的：银屑病关节炎（PsA）是一种影响银屑病患者关节和皮肤的慢性炎症性疾病。在这篇综述中，我们旨在总结现有证据，说明Janus激酶抑制剂（JAKi）用于治疗PsA时对患者报告结果（PROs）的影响：方法：我们采用叙事性综述的方法，在现有文献中寻找可纳入研究的文章：结果：研究发现，与安慰剂相比，JAKi能有效改善PRO反应。这些研究结果在不同的患者群体中是一致的，包括活动性PsA患者、对传统疗法反应不佳的患者以及合并症患者。支持JAKi对PsA患者PROs获益的证据令人信服，这些证据表明，JAKi在疼痛、身体功能、疲劳和生活质量方面的改善是一致的：结论：大量研究表明，JAKi对改善PsA患者的生活质量具有疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mediterranean Journal of Rheumatology Medicine-Rheumatology

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

8 weeks